{"id":163320,"date":"2023-05-04T13:23:48","date_gmt":"2023-05-04T18:23:48","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/05\/lilly-drug-slows-alzheimers"},"modified":"2023-05-04T13:23:48","modified_gmt":"2023-05-04T18:23:48","slug":"lilly-drug-slows-alzheimers","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/05\/lilly-drug-slows-alzheimers","title":{"rendered":"Lilly drug slows Alzheimer\u2019s"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/lilly-drug-slows-alzheimers2.jpg\"><\/a><\/p>\n<p>CHICAGO, May 3 (Reuters) \u2014 An experimental Alzheimer\u2019s drug developed by Eli Lilly and Co <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/LLY.N\" target=\"_blank\" class=\"\">(LLY.N)<\/a> slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.<\/p>\n<p>Lilly\u2019s drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer\u2019s by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer\u2019s proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death.<\/p>\n<p>The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO, May 3 (Reuters) \u2014 An experimental Alzheimer\u2019s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly\u2019s drug, [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-163320","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/163320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=163320"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/163320\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=163320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=163320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=163320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}